Clinical Trials Logo

Dyskinesia, Drug-Induced clinical trials

View clinical trials related to Dyskinesia, Drug-Induced.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03987750 Withdrawn - Parkinson Disease Clinical Trials

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Start date: October 2019
Phase: Phase 3
Study type: Interventional

This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced dyskinesia. Eligible participants will be randomized to one of three treatment groups to receive adjunctive daily treatment with either safinamide 100 mg, safinamide 150 mg or placebo in a 1:1:1 ratio. Outcome will be assessed after 26 weeks of treatment.